Compare Illumina, Inc. (ILMN) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Under Armour Inc Class A — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Under Armour Inc Class A trades at $4.78 (market cap $2.07B). The key difference: Illumina, Inc. is far larger — about 19.3× Under Armour Inc Class A's market cap, and Illumina, Inc. is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Under Armour Inc Class A for 18 Days on average.
| ILMN | UA | |
|---|---|---|
Market Cap | $39.95B | $2.07B |
Volume | 3,169,503 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $7.88 |
52-Week Low | $91.00 | $3.96 |
Typical Hold Time | 83 Days | 18 Days |
Enterprise Value | $41.31B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
Under Armour (UA) trades at $4.78, up 1.7% with a bullish technical signal despite negative profitability metrics. The company reported mixed quarterly results with two beats and one miss, while revenue declined to $4.9B in 2026 with a net loss of $492M. Analyst consensus shows 40% buy ratings but sentiment remains cautious due to ongoing revenue challenges and negative cash flow trends.
The outlook remains challenging with declining revenue and persistent losses, though the stock's low P/S ratio of 0.41 offers valuation support. Key risks include weak North American demand and competitive pressures, while potential catalysts require successful execution of turnaround strategies to restore profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
